International Journal of Innovative Technologies in Social Science
September 21, 2026
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the...
Expert Opinion on Therapeutic Targets
September 21, 2026
Sixtine Fleury, Katherine M. Nautiyal
INTRODUCTION: Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related pathology. AREAS COVERED: We synthesize converging evidence from human and...
Mental Health Weekly
September 21, 2026
Valerie A. Canady
As federal regulators consider the future role of psychedelic therapies, behavioral health leaders are urging early planning around workforce development, clinical training and equitable access. The U.S. Food and Drug Administration (FDA) on Sept. 14 convened a four‐hour public hearing with federal partners to examine the potential therapeutic use of psychedelic drugs.
Journal of Pain and Symptom Management
September 18, 2026
Megan Miller, Molly Meyers, Candace Oglesby-Adepoju et al.
Psilocybin-assisted therapy (PAT) shows promise for alleviating psychological and existential distress among people with cancer; however, research is limited by homogeneous samples, raising concerns about generalizability and equity. To explore perceptions and attitudes of PAT among a subset of people with cancer who have been underrepresented in research. A qualitative descriptive study was...
Quality in Sport
September 17, 2026
Maciej Krzysztof Kisielewski, Natalia Fidut, Jakub Skrzypek et al.
Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturbances, including changes in cognitive skills, appetite, and sleep patterns....
Psychology Archives
September 16, 2026
Lukas A Basedow, Andreas Reis, Irina Falkenberg et al.
The intensity of altered states of consciousness (ASC) induced by a psychedelic represents a key mechanism underlying the therapeutic effects of psychedelic-assisted therapy (PAT). However, growing evidence suggests that expectations may contribute significantly to therapeutic effects of PAT. The present study examined whether a psychedelic placebo could induce an ASC in a PAT- analogous...
ACS Chemical Neuroscience
September 15, 2026
Lindsay P. Cameron, Matthew W. Johnson, Kevin S. Murnane et al.
Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the...
Frontiers in Psychiatry
September 15, 2026
Serena Chiara Civardi, Filippo Besana, Federico Durbano et al.
Background Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for...
Psychotropes
September 15, 2026
Zoë Dubus
Durant la première vague d’études occidentales sur les propriétés thérapeutiques du LSD, l’une de ses indications principales dans le modèle « psychédélique » (administration de fortes doses en une à trois séances, surtout utilisée en Amérique du Nord) concerne le traitement de la dépendance à l’alcool. À l’inverse, en Europe, où se développait le modèle « psycholytique » (faibles doses...
Translational Psychiatry
September 14, 2026
Muhammad Asim, Julia A. Galiza Soares, Jason M Tucciarone
Serotonin (5-hydroxytryptamine; 5-HT) modulates a vast array of brain functions via its diverse receptor subtypes. Among these, the serotonin 5-HT2A receptor (5-HT2AR) has garnered intense recent interest for its pivotal role in mediating the effects of psychedelic compounds. Substantial evidence indicates that psychedelics act as agonists at the 5-HT2AR, triggering profound alterations in...